<DOC>
	<DOC>NCT01073865</DOC>
	<brief_summary>The purpose of this study is to examine the efficacy and safety as well as the characteristics of the female hormone and study medications after administration in pre-menopausal women with advanced or recurrent breast cancer who were randomised in a 1:1 ratio to either of the two treatment groups; the ZD9393 3.6 mg depot group or ZD9393 10.8 mg depot group, both given in combination with tamoxifen tablets.</brief_summary>
	<brief_title>Study to Compare Zoladex™ 10.8 mg With Zoladex 3.6 mg in Pre-menopausal Women With Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Goserelin</mesh_term>
	<mesh_term>Estrogens</mesh_term>
	<criteria>Female ≥20 years and premenopausal.Premenopausal defined as 1) last menses within 1 year of randomisation, and 2) E2 ≥10 pg/mL and FSH ≤ 30 mIU/mL within 4 weeks of randomisation. For patients who have had a hysterectomy, it is acceptable to meet only Hormone sensitivity (ER positive) of primary or secondary tumour tissue. Histological/cytological confirmation of breast cancer and are candidates to receive hormonal therapy as therapy for advanced breast cancer. Patients who have received tamoxifen or other hormonal therapies as adjuvant therapy for breast cancer within 24 weeks before randomisation and/or who have received prior treatment with hormonal therapies for advanced breast cancer Patients who have received LHRHa as adjuvant therapy for breast cancer within 48 weeks before randomisation Patients who have relapsed during adjuvant hormonal therapy or within 48 weeks after completion of adjuvant hormonal therapy and/or</criteria>
	<gender>Female</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>130 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>ZOLADEX</keyword>
	<keyword>Pre-menopausal</keyword>
	<keyword>Oestrogen Receptor</keyword>
	<keyword>Advanced Breast Cancer</keyword>
	<keyword>Progression Free Survival</keyword>
</DOC>